Table 1.
Baseline characteristics
| Variables | All Subjects | No Metabolic Syndrome | Metabolic Syndrome | P Value |
|---|---|---|---|---|
| n | 10 | 4 | 6 | |
| Age, yr | 46 ± 22 | 36 ± 7 | 52 ± 26 | 0.27 |
| Sex (M/F) | 6/4 | 3/1 | 3/3 | 0.57 |
| BMI, kg/m2 | 34 ± 2 | 33 ± 1 | 34 ± 3 | 0.72 |
| Waist, cm | 106 ± 14 | 102 ± 15 | 108 ± 14 | 0.54 |
| Hip, cm | 113 ± 11 | 114 ± 14 | 112 ± 10 | 0.81 |
| Body fat content, kg | 38 ± 10 | 36 ± 10 | 39 ± 11 | 0.60 |
| Android fat mass, kg | 4.0 ± 1.5 | 3.8 ± 1.8 | 4.1 ± 1.5 | 0.70 |
| Gynoid fat mass, kg | 6.6 ± 1.9 | 6.5 ± 2.0 | 6.6 ± 2.1 | 0.95 |
| Adipocyte diameter, μm | 95.5 ± 6.2 | 94.0 ± 7.1 | 96.4 ± 6.2 | 0.63 |
| SBP, mmHg | 136 ± 14 | 132 ± 9 | 139 ± 17 | 0.52 |
| DBP, mmHg | 75 ± 10 | 76 ± 14 | 74 ± 8 | 0.80 |
| Triglyceride, mmol/l | 1.38 ± 0.90 | 0.90 ± 0.19 | 1.70 ± 1.06 | 0.18 |
| HDL, mmol/l | 1.2 ± 0.3 | 1.6 ± 0.2 | 1.0 ± 0.2 | < 0.05 |
| LDL, mmol/l | 2.8 ± 0.6 | 2.9 ± 0.03 | 2.7 ± 0.8 | 0.59 |
| VLDL, mmol/l | 0.65 ± 0.41 | 0.41 ± 0.10 | 0.78 ± 0.49 | 0.19 |
| Plasma NEFA, nmol/ml | 190 ± 72 | 154 ± 47 | 214 ± 79 | 0.22 |
| AUCNEFA 30–120, nmol/ml·min | 6,074 ± 1,428 | 5,395 ± 1,878 | 6,526 ± 970 | 0.24 |
| Fasting glucose, mmol/l | 5.5 ± 0.5 | 4.8 ± 0.6 | 5.2 ± 0.4 | 0.28 |
| Glucose, 2-h OGTT, mmol/l | 7.5 ± 1.9 | 6.2 ± 1.7 | 8.4 ± 1.6 | 0.06 |
| Fasting insulin, pmol/l | 52.5 ± 34.0 | 39.0 ± 13.8 | 61.4 ± 13.8 | 0.33 |
| Muscle-ISI | 0.082 ± 0.04 | 0.11 ± 0.03 | 0.06 ± 0.04 | 0.10 |
| Plasma adiponectin, μg/ml | 4.2 ± 2.5 | 4.9 ± 3.2 | 3.8 ± 2.0 | 0.54 |
Data are presented as means ± SD. SBP, systolic blood pressure; DBP, diastolic blood pressure; Muscle-ISI, muscle insulin sensitivity. P values were computed using Student's t-test for comparison of no metabolic syndrome and metabolic syndrome subgroups. Difference in sex composition of no metabolic syndrome and metabolic syndrome subgroups was analyzed using Fisher's exact test.